BAJAJ BROKING

Notification
No new Notification messages
Ather Energy IPO is Open!
Apply for the Ather Energy IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

9581

542650

METROPOLIS

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

METROPOLIS HEALTHCARE LTD performance

Today’s low

Today’s high

₹ 1696.10 ₹ 1731.30
₹ 1701.50

52 week low

52 week high

₹ 1315.00 ₹ 2318.30
₹ 1701.50

Open Price

₹ 1727.80

Prev. Close

₹ 1704.80

Volume (Shares)

94802.00

Total traded value

₹ 1613.05

Upper Circuit

₹ 2045.70

Lower Circuit

₹ 1363.90

info

METROPOLIS HEALTHCARE LTD Share Price Update

As of the latest trading session, METROPOLIS HEALTHCARE LTD share price is currently at ₹ 1700, which is down by ₹ -4.80 from its previous closing. Today, the stock has fluctuated between ₹ 1696.10 and ₹ 1731.30. Over the past year, METROPOLIS HEALTHCARE LTD has achieved a return of -4.97 %. In the last month alone, the return has been 11.77 %. Read More...

METROPOLIS HEALTHCARE LTD fundamentals


  • Market cap (Cr)

    8,708.56

  • P/E Ratio (TTM)

    65.92

  • Beta

    0.83

  • Book Value / share

    215.63

  • Return on equity

    11.78%

  • EPS (TTM)

    25.88

  • Dividend yield

    0.23%

  • Net profit/quarter (Cr)

    27.40

info icon alternate text
  • Market cap (Cr)

    8,738.79

  • P/E Ratio (TTM)

    65.92

  • Beta

    0.77

  • Book Value / share

    215.63

  • Return on equity

    11.78%

  • EPS (TTM)

    25.88

  • Dividend yield

    0.23%

  • Net profit/quarter (Cr)

    27.40

info icon alternate text

METROPOLIS HEALTHCARE LTD Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 296.88
Operating Expense 263.12
Net Profit 27.40
Net Profit Margin (%) 9.22
Earnings Per Share (EPS) 5.35
EBITDA 68.14
Effective Tax Rate (%) 25.54
Particulars SEP 2024 (Values in Cr)
Revenue 321.57
Operating Expense 270.29
Net Profit 42.26
Net Profit Margin (%) 13.14
Earnings Per Share (EPS) 8.24
EBITDA 85.61
Effective Tax Rate (%) 22.96
Particulars JUN 2024 (Values in Cr)
Revenue 286.14
Operating Expense 247.24
Net Profit 31.28
Net Profit Margin (%) 10.93
Earnings Per Share (EPS) 6.11
EBITDA 71.09
Effective Tax Rate (%) 25.02
Particulars MAR 2024 (Values in Cr)
Revenue 292.27
Operating Expense 249.23
Net Profit 31.78
Net Profit Margin (%) 10.87
Earnings Per Share (EPS) 6.20
EBITDA 75.94
Effective Tax Rate (%) 29.45
Particulars DEC 2023 (Values in Cr)
Revenue 269.41
Operating Expense 239.96
Net Profit 26.70
Net Profit Margin (%) 9.91
Earnings Per Share (EPS) 5.21
EBITDA 64.01
Effective Tax Rate (%) 22.89
Particulars MAR 2024 (Values in Cr)
Revenue 1103.43
Operating Expense 958.02
Net Profit 115.89
Net Profit Margin (%) 10.50
Earnings Per Share (EPS) 22.63
EBITDA 270.48
Effective Tax Rate (%) 26.37
Particulars MAR 2023 (Values in Cr)
Revenue 1066.04
Operating Expense 908.38
Net Profit 138.95
Net Profit Margin (%) 13.03
Earnings Per Share (EPS) 27.14
EBITDA 290.59
Effective Tax Rate (%) 22.35
Particulars MAR 2022 (Values in Cr)
Revenue 1157.01
Operating Expense 917.51
Net Profit 199.53
Net Profit Margin (%) 17.24
Earnings Per Share (EPS) 39.00
EBITDA 351.41
Effective Tax Rate (%) 26.51
Particulars MAR 2021 (Values in Cr)
Revenue 961.39
Operating Expense 731.56
Net Profit 182.65
Net Profit Margin (%) 18.99
Earnings Per Share (EPS) 35.88
EBITDA 293.58
Effective Tax Rate (%) 24.56
Particulars MAR 2020 (Values in Cr)
Revenue 665.31
Operating Expense 530.10
Net Profit 112.05
Net Profit Margin (%) 16.84
Earnings Per Share (EPS) 22.32
EBITDA 177.40
Effective Tax Rate (%) 19.95
Particulars MAR 2024 (Values in Cr)
Book Value / Share 213.98
ROE % 12.33
ROCE % 15.72
Total Debt to Total Equity 0.22
EBITDA Margin 24.60
Particulars MAR 2023 (Values in Cr)
Book Value / Share 192.97
ROE % 15.30
ROCE % 17.23
Total Debt to Total Equity 0.34
EBITDA Margin 26.87
Particulars MAR 2022 (Values in Cr)
Book Value / Share 173.18
ROE % 26.96
ROCE % 30.24
Total Debt to Total Equity 0.31
EBITDA Margin 31.07
Particulars MAR 2021 (Values in Cr)
Book Value / Share 138.23
ROE % 29.81
ROCE % 35.83
Total Debt to Total Equity 0.15
EBITDA Margin 30.24
Particulars MAR 2020 (Values in Cr)
Book Value / Share 103.40
ROE % 30.60
ROCE % 39.47
Total Debt to Total Equity 0.09
EBITDA Margin 28.59
Particulars MAR 2024 (Values in Cr)
Book Value / Share 201.30
ROE % 11.78
ROCE % 15.02
Total Debt to Total Equity 0.24
EBITDA Margin 24.96
Particulars MAR 2023 (Values in Cr)
Book Value / Share 182.78
ROE % 15.65
ROCE % 17.19
Total Debt to Total Equity 0.36
EBITDA Margin 27.69
Particulars MAR 2022 (Values in Cr)
Book Value / Share 164.00
ROE % 26.53
ROCE % 29.41
Total Debt to Total Equity 0.32
EBITDA Margin 30.80
Particulars MAR 2021 (Values in Cr)
Book Value / Share 130.06
ROE % 31.03
ROCE % 37.36
Total Debt to Total Equity 0.14
EBITDA Margin 30.91
Particulars MAR 2020 (Values in Cr)
Book Value / Share 101.20
ROE % 27.96
ROCE % 34.60
Total Debt to Total Equity 0.08
EBITDA Margin 30.87
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 71.21
Total Assets 1555.06
Total Liabilities 1555.06
Total Equity 1099.27
Share Outstanding 51226861
Price to Book Ratio 8.58
Return on Assets (%) 8.21
Return on Capital (%) 11.63
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 93.19
Total Assets 1501.60
Total Liabilities 1501.60
Total Equity 990.71
Share Outstanding 51210664
Price to Book Ratio 6.83
Return on Assets (%) 9.51
Return on Capital (%) 13.36
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 166.93
Total Assets 1530.29
Total Liabilities 1530.29
Total Equity 888.16
Share Outstanding 51172119
Price to Book Ratio 12.42
Return on Assets (%) 13.99
Return on Capital (%) 18.68
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 419.69
Total Assets 1004.41
Total Liabilities 1004.41
Total Equity 708.06
Share Outstanding 51116813
Price to Book Ratio 17.23
Return on Assets (%) 18.22
Return on Capital (%) 25.86
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 210.47
Total Assets 752.23
Total Liabilities 752.23
Total Equity 525.15
Share Outstanding 50630566
Price to Book Ratio 12.71
Return on Assets (%) 16.92
Return on Capital (%) 24.25
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 30.46
Total Assets 1472.70
Total Liabilities 1472.70
Total Equity 1031.18
Share Outstanding 51226861
Price to Book Ratio 8.58
Return on Assets (%) 7.86
Return on Capital (%) 11.24
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 42.94
Total Assets 1434.29
Total Liabilities 1434.29
Total Equity 936.01
Share Outstanding 51210664
Price to Book Ratio 6.83
Return on Assets (%) 9.68
Return on Capital (%) 13.64
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 115.35
Total Assets 1458.54
Total Liabilities 1458.54
Total Equity 839.20
Share Outstanding 51172119
Price to Book Ratio 12.42
Return on Assets (%) 13.68
Return on Capital (%) 18.18
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 380.62
Total Assets 939.12
Total Liabilities 939.12
Total Equity 664.80
Share Outstanding 51116813
Price to Book Ratio 17.23
Return on Assets (%) 19.44
Return on Capital (%) 27.47
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 132.00
Total Assets 688.29
Total Liabilities 688.29
Total Equity 512.38
Share Outstanding 50630566
Price to Book Ratio 12.71
Return on Assets (%) 16.27
Return on Capital (%) 21.87
Particulars MAR 2024 (Values in Cr)
Net Income 174.68
Cash from Operations 301.45
Cash from Investing -89.41
Cash from Financing -181.19
Net change in Cash -6.54
Free Cash Flow 365.21
Particulars MAR 2023 (Values in Cr)
Net Income 187.50
Cash from Operations 298.66
Cash from Investing 46.79
Cash from Financing -292.32
Net change in Cash 1.55
Free Cash Flow 351.30
Particulars MAR 2022 (Values in Cr)
Net Income 293.35
Cash from Operations 335.78
Cash from Investing -737.57
Cash from Financing 162.52
Net change in Cash -321.77
Free Cash Flow 366.44
Particulars MAR 2021 (Values in Cr)
Net Income 244.32
Cash from Operations 305.86
Cash from Investing 61.70
Cash from Financing -32.69
Net change in Cash 278.03
Free Cash Flow 334.13
Particulars MAR 2020 (Values in Cr)
Net Income 168.73
Cash from Operations 279.42
Cash from Investing -104.83
Cash from Financing -55.32
Net change in Cash 54.84
Free Cash Flow 315.63
Particulars MAR 2024 (Values in Cr)
Net Income 157.40
Cash from Operations 296.26
Cash from Investing -81.00
Cash from Financing -182.99
Net change in Cash 5.00
Free Cash Flow 329.01
Particulars MAR 2023 (Values in Cr)
Net Income 178.94
Cash from Operations 281.76
Cash from Investing 46.72
Cash from Financing -287.86
Net change in Cash -3.40
Free Cash Flow 288.80
Particulars MAR 2022 (Values in Cr)
Net Income 271.54
Cash from Operations 320.21
Cash from Investing -738.21
Cash from Financing 171.97
Net change in Cash -322.19
Free Cash Flow 357.15
Particulars MAR 2021 (Values in Cr)
Net Income 242.12
Cash from Operations 291.29
Cash from Investing 59.41
Cash from Financing -31.26
Net change in Cash 264.37
Free Cash Flow 317.83
Particulars MAR 2020 (Values in Cr)
Net Income 139.99
Cash from Operations 203.74
Cash from Investing -51.12
Cash from Financing -46.37
Net change in Cash 58.63
Free Cash Flow 226.48
Company Name Price P/E P/B Market Cap 52 Week Low/High
APOLLO HOSPITALS ENTER. L 6992.60 76.74 13.41 100542.86 5690.80 / 7545.10
FORTIS MALAR HOSPITALS LIMITED 78.74 192.05 4.94 147.57 51.01 / 98.70
SHREE PACETRONIX LTD. 71.00 14.79 1.90 25.56 61.11 / 268.50
TRANSGENE BIOTEK LTD. 3.75 0.00 2.62 28.41 3.22 / 10.84
Company Name Price P/E P/B Market Cap 52 Week Low/High
APOLLO HOSPITALS ENTER. L 6992.60 83.66 12.27 100542.86 5690.80 / 7545.10
Surlux Diagnostic Ltd 1.40 0.84 0.13 0.49 0.00 / 0.00
CHENNAI MEENAKSHI MULTISPECIAL 31.25 0.00 -16.74 23.34 28.34 / 59.90
KOVAI MEDICAL CENTER & HOSPITA 5584.95 29.60 6.27 6109.94 3750.00 / 6400.00

METROPOLIS HEALTHCARE LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
1701.50 -0.19 redarrow
red-green-graph indicator
8 Bearish
8 Bullish
  • 5 Days 1728.30
  • 26 Days 1664.50
  • 10 Days 1706.30
  • 50 Days 1684.00
  • 12 Days 1696.90
  • 100 Days 1770.10
  • 20 Days 1671.70
  • 200 Days 1838.20
1719.57 PIVOT

First Support

1685.23

First Resistance

1739.13

Second Support

1665.67

Second Resistance

1773.47

Third Support

1631.33

Third Resistance

1793.03

RSI

56.27

ADX

22.37

MACD

32.43

Williams % R

-17.59

Commodity Channel Index (CCI)

73.82

Date

2025-04-29

Week

30611.00

Same Day

9971.00

Month

52907.00

1 Year

0.84

3 Year

0.80

Over 1 Month

11.77%

down

Over 1 Year

-4.97%

down

Over 3 Months

-4.83%

down

Over 3 Years

-10.74%

down

Over 6 Months

-19.55%

down

Over 5 Years

6.57%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

METROPOLIS HEALTHCARE LTD shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
5.52%
Promoter Holdings
48.89%
FII
15.28%
DII
30.29%
Promoter Shares(Pledge Percentage)
1.18%
Name Shares Category
Metz Advisory Llp 1.5691216E7 (30.29%) Shareholding of Promoter and Promoter Group
Duru Shah Family Trust 5729685.0 (11.06%) Shareholding of Promoter and Promoter Group
Hdfc Mutual Fund - Hdfc Focused 30 Fund 4995968.0 (9.64%) Public Shareholding
Sushil Shah Family Trust 2558187.0 (4.94%) Shareholding of Promoter and Promoter Group
Uti Value Fund 1851655.0 (3.57%) Public Shareholding
Kotak Small Cap Fund 1514166.0 (2.92%) Public Shareholding
Nippon Life India Trustee Ltd-a/c Nippon India Small Cap Fund 1180052.0 (2.28%) Public Shareholding
Sushil Kanubhai Shah 1167058.0 (2.25%) Shareholding of Promoter and Promoter Group
Sbi Life Insurance Co. Ltd 1094676.0 (2.11%) Public Shareholding
Franklin India Smaller Companies Fund 1080518.0 (2.09%) Public Shareholding
J P Morgan Funds 823376.0 (1.59%) Public Shareholding
Aditya Birla Sun Life Trustee Private Limited A/c Aditya Birla Sun Life Flexi Cap Fund 796022.0 (1.54%) Public Shareholding
Sundaram Mutual Fund A/c Sundaram Services Fund 777704.0 (1.5%) Public Shareholding
Canara Robeco Mutual Fund A/c Canara Robeco Small Cap Fund 582930.0 (1.13%) Public Shareholding
Jpmorgan Indian Investment Trust Plc 559353.0 (1.08%) Public Shareholding
Core Diagnostics (mauritius) Private Limited 518920.0 (1.0%) Public Shareholding
Ameera Sushil Shah 181845.0 (0.35%) Shareholding of Promoter and Promoter Group
Duru Sushil Shah 0.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

METROPOLIS HEALTHCARE LTD corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
17 Nov 2023 4.0 Interim 17 Nov 2023 Equity shares
23 Feb 2023 8.0 Interim 23 Feb 2023 Equity shares
21 Feb 2022 8.0 Interim 22 Feb 2022 Equity shares
17 Feb 2021 8.0 Interim 19 Feb 2021 Equity shares
13 Feb 2020 8.0 Interim 15 Feb 2020 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
17 Nov 2023 4.0 Interim 17 Nov 2023 Equity shares
23 Feb 2023 8.0 Interim 23 Feb 2023 Equity shares
21 Feb 2022 8.0 Interim 22 Feb 2022 Equity shares
17 Feb 2021 8.0 Interim 19 Feb 2021 Equity shares
13 Feb 2020 8.0 Interim 15 Feb 2020 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

METROPOLIS HEALTHCARE LTD Share Price

Dr. Sushil Kanubhai Shah, one of the Promoters, commenced pathology business in January 1980 as a partnership firm in the name of Dr. V. K. Desai's Hospital, having Dr. Kanubhai M. Shah, Dr. Sushil Kanubhai Shah and Dr. Vasant Kalyandas Desai as partners. The partnership was continued by Dr. Sushil Kanubhai Shah, Dr. Kanubhai M. Shah and Dr. Duru Sushil Shah from September 30, 1981 onwards. In June 1989, upon death of Dr. Kanubhai M. Shah, the partnership was continued by Dr. Sushil Kanubhai Shah and Dr. Duru Sushil Shah. Prior to March 18, 1995, Dr. Sushil Kanubhai Shah was also carrying on a business of radioimmunoassay and pathology laboratory on a sole proprietorship basis. On March 20, 1995, the said sole proprietorship business was converted into a partnership with Dr. Sushil Kanubhai Shah, Dr. Duru Sushil Shah and Aparna S. Shah (Rajadhyaksha) as partners, in the name and style of Metropolis Lab. In January 1998, Ameera Sushil Shah was inducted as an additional partner in Metropolis Lab.

With effect from February 1, 2002, the business of Metropolis Lab was transferred to Dr. V. K. Desai's Hospital as a going concern. In May 2002, Dr. G. S. K. Velu and Subbulakshmi K. Velu were admitted as partners in Dr. V. K. Desai Hospitals. The name of Dr. V. K. Desai's Hospital was changed to Metropolis Health Services in November 2002. Further, in April 2003, Ameera Sushil Shah, Jaswanti Kanubhai Shah, Sadacharan Gomanthybabu and Gomathybabu Gomathy were admitted as partners in Metropolis Health Services.

In July 2003, Metropolis Health Services was converted into a private limited company as Metropolis Health Services (India) Private Limited ('MHSIPL'). The name of MHSIPL was changed to Metropolis Health Services (India) Limited ('MHSIL') pursuant to a Fresh Certificate of Incorporation Consequent upon Change of Name on Conversion to Public Limited Company' on March 1, 2006. In January 2009, MHSIL amalgamated with Pathnet India Private Limited, which was a wholly owned subsidiary of MHSIL.

Metropolis Healthcare Ltd (Formerly known as Pathnet India Private Limited) was incorporated at New Delhi on November 10, 2000. The Company is one of the leading diagnostics companies in India. It has widespread presence across 220 cities in India with leadership position in West and South India. Through its widespread operational network, it offers a comprehensive range of clinical laboratory tests and profiles, which are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of the disease. It also offers analytical and support services to clinical research organizations for their clinical research projects. Presently, it is engaged in the business of providing pathology and related healthcare services.

The Company conducts its operations through their laboratory and service network. It has implemented a hub and spoke' model for quick and efficient delivery of services through their widespread laboratory and service network, which covers 197 cities in India. As of December 31, 2018, its laboratory network consists of 115 clinical laboratories, comprising (i) a global reference laboratory ('GRL') located in Mumbai, which is the main hub' and equipped to conduct majority of the tests offered by them; (ii) 14 regional reference laboratories ('RRLs') (out of which four are located outside India), which are equipped to conduct routine, semi-specialized and few specialized tests; (iii) 56 satellite laboratories (out of which one is located outside India), which are equipped to conduct routine and semi-specialized tests; and (iv) 44 express laboratories (out of which five are located outside India), which are equipped to conduct routine tests.

Metropolis Healthcare has been awarded the tender by the National Aids Control Organization ('NACO') to collect specimens from 525 government-owned antiretroviral therapy (ART) centers and conduct HIV-1-Viral load tests. It also offers analytical services and support services such as logistics and electronic data interchange ('EDI') to contract research organizations for their clinical research projects.

Outside India, it has laboratory operations in Ghana, Kenya, Zambia, Mauritius and Sri Lanka. In addition, it has also entered into agreements with third parties for collection and processing of specimens in Nepal, Nigeria, UAE and Oman.

Metropolis' brand is recognized for delivering quality diagnostic and related healthcare tests and services. For instance, it received 'excellence in customer service and delivery' award from Biotrains in 2018, and also received special jury mention for 'service excellence (diagnostic center)' by FICCI at the Healthcare Excellence Awards 2018. In addition, its health campaign was recognized as 'best in health and fitness' in the Digital Campaign Awards 2018 by LH Insights.

Metropolis Healthcare Ltd. came out with an Initial Public Offering (IPO) of 13,685,095 equity shares of Face Value of Rs 2/- each of the company for cash at a price of Rs 880 per equity share aggregating Rs 1204.29 Crores, consisting of an offer for sale of 6,272,335 equity shares by Dr. Sushil Kanubhai Shah (the promoter selling shareholder) aggregating to 551.97 Crores and 7,412,760 equity shares by Ca Lotus Investments (the investor selling shareholder) aggregating 652.32 Crores. The face value of equity shares is Rs 2/-each. The IPO was priced at Rs 880 per equity share.

During the year 2018-19, the Wholly Owned Subsidiaries viz., Bacchus Hospitality Services and Real Estate Private Limited; Metropolis Healthcare (Chandigarh) Private Limited, Metropolis Healthcare (Jodhpur) Private Limited, Sanket Metropolis Health Services (India) Private Limited, Final Diagnosis Private Limited and Golwilkar Metropolis Health Services (India) Private Limited amalgamated with the Company (Transferee Company) effective from 08 September 2018. Further, the Transferee Company on 08 September 2018 allotted 26,57,731 fully paid up Equity Shares of Rs 10/- each in the ratio of 957,713 Equity Shares of Rs 10/- each to the shareholders of Bacchus for every 10,00,000 Equity Shares of Rs 10/- each held in Bacchus (Pre-bonus and Sub-division).

The wellness initiative TruHealth' was launched across 36cities in FY19; launched Medengage, to nurture upcoming medical talent. A wide range of ~3,487 clinical laboratory tests and 530 profiles were offered by Metropolis as of March 2019. The equity shares of Company were listed on BSE Ltd and the National Stock Exchange of India Limited with effect from April 15, 2019.

The Company acquired four frontend labs in Surat in FY 2020. It acquired 51% of stake i.e. 5,100 Equity Shares of Shraddha Diagnostic Centre (I) Private Limited (SDCIPL) from the existing shareholders at a consideration of Rs 9,36,30,000/-. It further acquired a total of 550 equity shares of the Target Company (constituting 5.5 % of its Share Capital) on April 7, 2020 for a consideration of Rs 1 Crores.

During the year 2020-21, the Company acquired the balance stake of 49% in Raj Metropolis and with effect from November 5, 2020 and as a result, Raj Metropolis became a wholly-owned subsidiary of the Company.

In the financial year 2021-22, Metropolis strengthened its operations by adding 16 labs and 506 network centres, as a part of expansion plan of adding 90 labs and 1,800 network centres by FY 24. It acquired the 100% stake in Dr. Ganesan's Hitech Diagnostics Centre Private Limited along with its subsidiary Centralab Healthcare Services Private Limited and post completion of acquisition, Hitech and Centralab became wholly-owned subsidiary and step down wholly owned subsidiary respectively of Company effective 22 Oct' 2021. Similarly, during the year 2021-22, Company had acquired balance stake of 35% of Metropolis Histoexpert Digital Services Private Limited, Subsidiary of the Company from Koninklijke Philips N.V. Post the acquisition, Metropolis Histoxpert became the wholly-owned
Subsidiary of the Company with effect from 26 November 2021.

During the year 2022-23, the Company launched some complex tests using Next Generation Sequencing (NGS) Technology for Pre-natal screening, Breast Cancer, Bone Marrow Transplant and Allergy Component Testing powered by Artificial Intelligence. In FY 23, it added 14 labs and approximately 548 centers during the year, built a new management team to run the business, integrated the technology offering with Metropolis and executed some cost synergies; further added 83 new tests.

During year 2022-23, the subsidiary companies, M/s. Bokil Golwilkar Metropolis Healthcare Private Limited, M/s. Desai Metropolis Health Services Private Limited, M/s. Dr. Patel Metropolis Healthcare Private Limited, M/s. Lab One Metropolis Healthcare Services Private Limited, M/s. Micron Metropolis Healthcare Private Limited, M/s. R. V. Metropolis Diagnostic & Health Care Center Private Limited, M/s. Raj Metropolis Healthcare Private Limited and M/s. Sudharma Metropolis Health Services Private got merged with the Company through the Scheme of Amalgamation, which was made effective from July 11, 2022.

Parent organization Indian Private
NSE symbol METROPOLIS
Founded 2000
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Metropolis Healthcare Ltd?

Answer Field

The share price of Metropolis Healthcare Ltd for NSE is ₹ 1700 and for BSE is ₹ 1705.9.

What is the Market Cap of Metropolis Healthcare Ltd?

Answer Field

The market cap of Metropolis Healthcare Ltd for NSE is ₹ 87,08.56 Cr. and for BSE is ₹ 87,38.79 Cr. as of now.

What is the 52 Week High and Low of Metropolis Healthcare Ltd?

Answer Field

The 52 Week High and Low of Metropolis Healthcare Ltd for NSE is ₹ 2318.30 and ₹ 1315.00 and for BSE is ₹ 2306.85 and ₹ 1383.70.

How to Buy Metropolis Healthcare Ltd share?

Answer Field

You can trade in Metropolis Healthcare Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Metropolis Healthcare Ltd?

Answer Field

The 1 year returns on the stock has been -4.97%.

What is the Current Share Price of Metropolis Healthcare Ltd?

Answer Field

Metropolis Healthcare Ltd share price is for NSE ₹ 1700 & for BSE ₹ 1705.9 as on Apr 30 2025 03:29 PM.

What is the Market Cap of Metropolis Healthcare Ltd Share?

Answer Field

The market cap of Metropolis Healthcare Ltd for NSE ₹ 87,08.56 & for BSE ₹ 87,38.79 as on Apr 30 2025 03:29 PM.

What is the P/E Ratio of Metropolis Healthcare Ltd Share?

Answer Field

As on Apr 30 2025 03:29 PM the price-to-earnings (PE) ratio for Metropolis Healthcare Ltd share is 65.92.

What is the PB ratio of Metropolis Healthcare Ltd Share?

Answer Field

As on Apr 30 2025 03:29 PM, the price-to-book (PB) ratio for Metropolis Healthcare Ltd share is 215.63.

How to Buy Metropolis Healthcare Ltd Share?

Answer Field

You can trade in Metropolis Healthcare Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Metropolis Healthcare Ltd Share on Bajaj Broking App?

Answer Field

To buy Metropolis Healthcare Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Metropolis Healthcare Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|